Oxaprozin, also known as oxaprozinum, is a nonsteroidal anti-inflammatory drug (NSAID),[2] used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis.

Safety and efficacy has been established in children over 6 years with juvenile rheumatoid arthritis only, and there is an increased risk of adverse reactions in the elderly population.

After etoricoxib, patients taking oxaprozin experienced the least amount of pain with fewer adverse effects than naproxen.

[9][10] In December 1988, Wyeth-Ayerst licensed the marketing rights for the US, Canada, Puerto Rico, and the Caribbean to Searle.

Upon its release, “The Pink Sheet” estimated that the average whole sale price of Searle's Daypro was $112.30 for 100 (600 mg) tablets.

[7] Since the approval of Daypro by Searle, other companies have submitted abbreviated new drug applications (ANDAs) to the FDA.